COVID-19 Resources for the Pancreatic Cancer Patient: We are Behind you, Every Step of the Way
We are committed to assisting pancreatic cancer patients to find information during this challenging time with the COVID-19 pandemic. Below are some useful resources.
- Pancreatic Cancer Action: Coronavirus (COVID-19) Resource Center
- Pancreatic Cancer Action Network: Navigating Pancreatic Cancer Care During the Coronavirus Crisis
- Lustgarten Foundation for Pancreatic Research: What Pancreatic Cancer Patients Should Know About COVID-19
- Let’s Win Pancreatic Cancer: Pancreatic Cancer Treatment During the COVID-19 Pandemic
- American Society of Clinical Oncology
- ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era: Pancreatic Cancer
Pancreatic cancer is on the rise. The number of cases of pancreatic cancer is also increasing globally. In 2018, approximately 460,000 new cases of pancreatic cancer were reported.
Although advances in cancer treatments continue to grow, there is still a great need for new therapies. Promising new treatment options and ways to deliver these treatments more effectively are now under development.
Do you have locally advanced pancreatic cancer that cannot be treated surgically and has not spread to other parts of your body?
- We are currently looking for men and women who have been diagnosed with pancreatic cancer who may be interested in joining a clinical research study called the TIGeR-PaC Study.
- The TIGeR-PaC Study is investigating a new way of administering chemotherapy in people with pancreatic cancer.
- If you qualify for the study, study medicine and all study-related care will be provided at no additional cost by your insurance or Company conducting the TIGeR-PaC Study.
- Participation in the TIGeR-PaC Study is voluntary, and you can leave the study at any time, for any reason.
Patient Stories
Watch news reports of real patients undergoing targeted diagnostic and therapeutic infusion using the RenovoCath, which is FDA cleared and now being investigated in an active clinical trial to prove extended median survival and improved quality of life.
RenovoRx on Twitter
Proud to announce 6th U.S. patent!
https://renovorx.com/renovorx-announces-issuance-of-sixth-u-s-patent/
Exciting news from our team! We have received a new orphan drug designation from FDA for treating bile duct cancer. https://renovorx.com/renovorx-announces-orphan-drug-designation-granted-for-treating-bile-duct-cancer/
Great meeting with TIGeR-PaC phase 3 clinical trial principal investigators and research team at the 2020 GI ASCO Symposium, last week in San Francisco. Looking forward to future collaborations in fighting Locally Advanced Pancreatic Cancer.
Let's Meet at ISET and ASCO GI 2020 Next Week: Learn More About the Phase III TIGeR-PaC Clinical Trial -- A Potential New Option for Patients with Pancreatic Cancer
http://www.icontact-archive.com/archive?c=1773977&f=6180&s=6814&m=115101&t=6573b40293439f53ef02c273f2ec76f6840517684a6eb7328a7e3eb308e482f6